Skip to main content

Non-Radiographic Axial Spondyloarthritis News

FDA Approves Novartis Cosentyx as First Intravenous (IV) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

EAST HANOVER, N.J., Oct. 6, 2023 /PRNewswire/ – Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved an...

Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Rinvoq is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) Rinvoq is the first and only JAK inhibitor approved for...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related drug support groups

Cosentyx